Amal Therapeutics becomes a subsidiary of a German Pharma giant

Amal Therapeutics becomes a subsidiary of a German Pharma giant

16.7.2019 – Since its establishment, Amal Therapeutics has raised more than €40 million in venture capital in addition to grants among others. The biotech startup and spinoff from the University of Geneva is now a subsidiary of the German pharma company, Boehringer Ingelheim, which acquired all shares of the latter for EUR 325 million.

read more…